cabozantinib sold brand names cometriq cabometyx among others anticancer medication used treat medullary thyroid cancer renal cell carcinoma hepatocellular small molecule inhibitor tyrosine kinases cmet also inhibits axl discovered developed exelixis inc november cabozantinib capsule formulation approved us food drug administration fda name cometriq treating people medullary thyroid capsule form approved european union purpose april fda granted approval marketing tablet formulation cabometyx second line treatment kidney approved european union september brands cometriq cabometyx different formulations cabozantinib used two forms capsule form cometriq used treat medullary thyroid tablet form cabometyx used treat renal cell carcinoma hepatocellular carcinoma differentiated thyroid cabozantinib tested pregnant women causes harm fetuses rodents pregnant women take drug women become pregnant taking known cabozantinib excreted breast us capsule formulation cometriq carries black box warning risk holes forming stomach intestines well formation fistulas tunnels gi tract black box also warns risk uncontrolled tablet formulation cabometyx warns effects labels also warn risk clots forming causing heart attacks strokes high blood pressure including hypertensive crisis osteonecrosis jaw severe diarrhea skin sloughing palms soles syndrome headaches confusion loss vision seizures protein appearing common adverse effects greater people include decreased appetite low calcium potassium phosphate magnesium levels high bilirubin levels distorted sense taste headache dizziness high blood pressure distorted sense hearing earaches sore throat diarrhea nausea constipation vomiting stomach pain upset stomach inflammation mouth lips burning sensation mouth skin sloughing palms soles hair color changes hair loss rash dry skin red skin joint pain muscle spasms fatigue weakness weight loss elevated transaminases higher cholesterol levels loss red white blood common adverse effects people include abscesses inside body skin teeth skin pneumonia inflamed hair follicles fungal infections low thyroid levels dehydration loss albumin anxiety depression confusion peripheral neuropathy tingling tremor tinnitus atrial fibrillation low blood pressure blocked veins paleness chills fistulas forming trachea esophagus blood clots lungs bleeding respiratory tract gi perforation bleeding stomach intestines pancreatitis hemorrhoids anal fissure anal inflammation gallstones hard skin growths acne blisters abnormal hair growth loss skin color skin flaking chest pain blood protein urine wounds dont heal well facial cabozantinib substrate multidrug resistanceassociated protein drugs inhibit enzymes increase halflife cabozantinib potentially increase adverse effects drugs activate may cause cabozantinib less cabozantinib inhibits following receptor tyrosine kinases met hepatocyte growth factor receptor protein vegfr ret receptor axl kit fmslike tyrosine cabozantinib granted orphan drug status us food drug administration fda november february exelixis filed new drug application fda november cabozantinib capsule formulation granted marketing approval fda name cometriq treating people medullary thyroid capsule form approved european union purpose march exelixis licensed ipsen worldwide rights outside us canada japan market april fda granted approval marketing tablet formulation second line treatment kidney approved european union september december fda granted approval cabozantinib cabometyx exelixis inc treatment people advanced renal cell carcinoma approval based data cabosun randomized openlabel phase ii multicenter study participants intermediate poorrisk previously untreated january fda approved cabozantinib cabometyx exelixis inc people hepatocellular carcinoma previously treated approval based celestial randomized doubleblind placebocontrolled multicenter trial participants hepatocellular carcinoma previously received sorafenib child pugh class liver impairment cabozantinib efficacy treatment renal cell carcinoma rcc hepatocellular carcinoma hcc cervical cancer colorectal cancer crc urothelial cancer prostate cancer gastric gastroesophageal cancer bladder cancer melanoma merkel cell carcinoma brain cancers including glioblastoma multiforme anaplastic astrocytoma nonsmall cell lung cancer nsclc adrenocortical carcinoma various sarcomas head neck squamous cell carcinomas hnscc breast cancer endometrial cancer neuroendocrine cancers neurofibromatosis type httpsenwikipediaorgwikicabozantinib